Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Marcela V Maus"'
Autor:
Nikhil C. Munshi, Christopher J. Gibson, Caron A. Jacobson, Peter Miller, Max Jan, Mark B. Leick, Geoffrey Fell, Benjamin L. Ebert, Marcela V. Maus, Elliott J. Brea, Yu-Tzu Tai, Satyen H. Gohil, Donna Neuberg, Catherine J. Wu, Adam S. Sperling
Publikováno v:
Blood Adv
Chimeric antigen receptor (CAR) T-cells have emerged as an efficacious modality in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Clonal hematopoiesis of indeterminate potential (CHIP), a state in which mutations in hematopoietic
Publikováno v:
Annual Review of Medicine. 72:365-382
Adoptive transfer of T cells modified with chimeric antigen receptors (CAR-T cells) has changed the therapeutic landscape of hematological malignancies, particularly for acute lymphoblastic leukemia and large B cell lymphoma, where two different CAR-
Publikováno v:
Cytometry Part B: Clinical Cytometry. 98:299-327
Chimeric antigen receptor (CAR) T cells provide a promising approach to the treatment of hematologic malignancies and solid tumors. Flow cytometry is a powerful analytical modality, which plays an expanding role in all stages of CAR T therapy, from l
Autor:
Marcela V. Maus, Matthew J. Frigault
Publikováno v:
J Clin Invest
Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations of novel constructs being developed at a rapid pace. Since the initial reports of chimeric antigen receptor T cell (CAR T cell)success in CD19(+) B cell ma
Autor:
Regina M. Myers, Carl H. June, David M. Barrett, Stephan A. Grupp, Rong Fan, J. Joseph Melenhorst, Pablo G. Camara, Dong-Joo Kim, Marcela V. Maus, Stefan Lundh, Steven Woodhouse, Zhiliang Bai
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundAutologous T cells engineered to express a chimeric antigen receptor (CAR) specific for CD19 molecule have transformed the therapeutic landscape in patients with highly refractory leukemia and lymphoma, and the use of donor-generated alloge
Autor:
Jennifer Y. Yam, Victoria Burgoyne, Kathleen Gallagher, Ulrika Johansson, Marcela V. Maus, Gabrielle Brini, Keagan S Casey, Nikesh Chavda, Sanne Lugthart, Caroline Besley, Matthew J. Frigault
Publikováno v:
Cytometry. Part B, Clinical cytometryREFERENCES. 100(6)
BACKGROUND Chimeric antigen receptor-modified T-cells targeting CD19 (CAR-T19) are licensed for treating relapsed/refractory diffuse large B-cell lymphoma and B-acute lymphoblastic leukemia. Predicting treatment responses and toxicity (e.g., cytokine
Publikováno v:
Autoimmunity
BACKGROUND AIM: T-Cell immunotherapies are rapidly gaining grounds in clinical success. Presently, there is first-to-market knowledge on the translation of research scale methods to clinical and commercial scales. Improved understanding can lead to m
Publikováno v:
Clinical Cancer Research. 25:2042-2048
Glioblastoma (GBM) is a devastating disease with an extremely poor prognosis. Immunotherapy via adoptive cell transfer (ACT), especially with T cells engineered to express chimeric antigen receptors (CAR), represents a particularly promising approach
Autor:
Crystal L. Mackall, Renier J. Brentjens, Madhav V. Dhodapkar, David G. Maloney, Stephan A. Grupp, Michael R. Bishop, Marcela V. Maus, Michael Boyiadzis, Carl H. June, Sattva S. Neelapu, David L. Porter, James N. Kochenderfer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Chimeric Antigen Receptor (CAR) T cell therapies – adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to thr
Autor:
Matthew J. Frigault, Scott J. Rodig, Alexandra J. Shay, Ana P. Castano, Alexandria Van Scoyk, Maria Ormhøj, Frederic I. Preffer, David M. Weinstock, Irene Scarfò, Jon C. Aster, Marcela V. Maus, Selena J. Lorrey, Amanda A. Bouffard
Publikováno v:
Scarfò, I, Ormhøj, M, Frigault, M J, Castano, A P, Lorrey, S, Bouffard, A A, Van Scoyk, A, Rodig, S J, Shay, A J, Aster, J C, Preffer, F I, Weinstock, D M & Maus, M V 2018, ' Anti-CD37 chimeric antigen receptor T cells are active against B-A nd T-cell lymphomas ', Blood, vol. 132, no. 14, pp. 1495-1506 . https://doi.org/10.1182/blood-2018-04-842708
Chimeric antigen receptor (CAR) T cells have emerged as a novel form of treatment of patients with B-cell malignancies. In particular, anti-CD19 CAR T-cell therapy has effected impressive clinical responses in B-cell acute lymphoblastic leukemia and